natgillin/translations-raw huggingface dataset:
19. Of the total operational commitments made in 2015 (193,5 million euro), 42,6 % were individual commitments based on completed award procedures for grants and contracts. 
17. Av de totala operativa taganden som gjordes 2015 (420,3 miljoner euro) var 50,2 % enskilda taganden som baserades p avslutade tilldelningsfrfaranden fr bidrag och kontrakt.
The remaining 57,3 % were global commitments for which the award procedure was not completed. 
De terstende 49,8 % var vergripande taganden fr vilka tilldelningsfrfarandet nnu inte var avslutat.
The high level of global commitments in 2015 is due to the time required for the evaluation and negotiation procedures for the 2015 calls for proposals for Horizon 2020 projects. 
Enskilda tagandens storlek 2015 beror p att frhandlings-frfarandet nr det gller anskningsomgngarna 2015 fr projekt inom Horisont 2020 var frsenat.
FCH Joint Undertaking multiannual budget implementation under FP7 20. 
Det gemensamma fretaget IMI:s genomfrande av den flerriga budgeten inom sjunde ramprogrammet 18.
Out of a total envelope of 470 million euro for the operational and administrative activities of the FCH Joint Undertaking to be funded by the EU under FP7, the Joint Undertaking made operational commitments of 453,1 million euro and payments of 316 million euro (69,8 % of operational commitments) by the end of 2015. 
Av den miljard euro fr det gemensamma fretaget IMI:s drift och administration som ska finansieras av EU inom sjunde ramprogrammet hade det gemensamma fretaget gjort taganden p 966 miljoner euro och betalningar p 538,1 miljoner euro (55,7 % av driftstagandena) i slutet av 2015.
The EU cash contribution to the Joint UndertakingŐs administrative costs amounted to 9 million euro. 
EU:s kontantbidrag till det gemensamma fretagets administrativa kostnader uppgick till 27,2 miljoner euro.
Out of a total envelope of 470 million euro for the other membersŐ in-kind and cash contributions to cover operational and administrative costs, 342,3 million euro of in-kind contributions to operational activities had been reported to the FCH Joint Undertaking by 31 December 2015, of which 185,6 million euro or 54,2 % have been validated by the Governing Board. 
19. Av den miljard euro i naturabidrag och kontantbidrag frn de vriga medlemmarna hade 503,1 miljoner euro i naturabidrag till driften rapporterats till det gemensamma fretaget IMI fre den 31 december 2015, varav 321,8 miljoner euro eller 63,9% har godknts av styrelsen.
The other membersŐ cash contributions to the administrative costs of the Joint Undertaking amounted to 13 million euro. 
De vriga medlemmarnas kontantbidrag till det gemensamma fretagets administrativa kostnader uppgick till 14,2 miljoner euro.
FCH Joint Undertaking multiannual budget implementation under Horizon 2020 22. 
Det gemensamma fretaget IMI:s genomfrande av den flerriga budgeten inom Horisont 2020 20.
Out of a total envelope of 665 million euro for the operational and administrative activities to be funded by the EU under Horizon 2020, the Joint Undertaking made operational commitments amounting to 83,6 million euro and payments amounting to 29,4 million euro (35 % of operational commitments). 
Av de totala anslagen p 1 638 miljoner euro fr drift och administration som ska finansieras av EU inom Horisont 2020 hade det gemensamma fretaget gjort driftstaganden p 351,7 miljoner euro och betalningar p 45,9 miljoner euro (13% av driftstagandena).
The EU cash contribution to the Joint UndertakingŐs administrative costs amounted to 781 000 euro. 
EU:s kontantbidrag till det gemensamma fretagets administrativa kostnader uppgick till 1,2 miljoner euro.
For the other membersŐ in-kind and cash contributions, out of a total envelope of 665 million euro, the Joint Undertaking estimated that 3,9 million euro of in-kind contributions to operational activities had been incurred by 31 December 2015. The other membersŐ cash contributions to the Joint UndertakingŐs administrative costs amounted to 781 000 euro. 
Inom de totala anslagen p 1 638 miljoner euro i naturabidrag och kontantbidrag hade 68,6 miljoner euro frn de vriga medlemmarna rapporterats till det gemensamma fretaget fre den 31 december 2015. De vriga medlemmarnas kontantbidrag till det gemensamma fretagets administrativa kostnader uppgick till 2,8 miljoner euro. VRIGT Nyckelkontroller och vervakningssystem 22.
The FCH Joint Undertaking has set up ex ante control procedures based on financial and operational desk reviews, and performs ex post audits of grant beneficiaries. 
Det gemensamma fretaget IMI har infrt frfaranden fr frhandskontroll som bygger p finansiella och operativa skrivbordsgranskningar och gr efterhandsrevisioner av bidragsmottagare.
These checks are key tools for assessing the legality and regularity of the underlying transactions, including the cash and in-kind contributions to the Joint Undertaking by its members other than the EU. 
Kontrollerna r nyckelverktyg fr att bedma lagligheten och korrektheten hos de underliggande transaktionerna, bland annat kontantbidrag och naturabidrag till det gemensamma fretaget frn andra medlemmar n EU.
The residual error rate for the ex post audits reported in the FCH Joint Undertaking Annual Activity Report in 2015 was 0,98 % (19). Anti-fraud strategy 25. 
Den kvarstende felprocenten fr de efterhandsrevisioner som rapporteras i det gemensamma fretagets rliga verksamhetsrapport 2015 var 1,5 % (14). Strategi fr bedrgeribekmpning 23.
According to Article 12 of the Financial Rules of the FCH Joint Undertaking, the budget should be implemented in compliance with effective and efficient internal control, including prevention, detection, correction and follow-up of fraud and irregularities. 
Enligt artikel 12 i det gemensamma fretagets finansiella regler ska budgeten flja reglerna om en ndamlsenlig och effektiv internkontroll som inbegriper tgrder fr att frebygga, upptcka, korrigera och flja upp bedrgerier och oriktigheter.
26. Following the adoption of an anti-fraud strategy by the European Commission in June 2011, the first common research anti-fraud strategy was adopted in July 2012, and updated in March 2015 to take account of changes introduced by Horizon 2020 (20). 
24. Efter att kommissionen hade antagit en strategi fr bedrgeribekmpning i juni 2011 antogs den frsta gemensamma bedrgeribekmpningsstrategin fr forskningsomrdet i juli 2012.
The research anti-fraud strategy includes an action plan to be implemented by the research Joint Undertakings. 
I bedrgeribekmpningsstrategin fr forskningsomrdet ingr en tgrdsplan som de gemensamma forskningsfretagen ska genomfra. 25.
Internal control procedures are already in place at the FCH Joint Undertaking to provide reasonable assurance on the prevention and detection of fraud and irregularities (ex ante checks on payments, conflict of interest policy and ex post audits of final beneficiaries of grants). 
Det gemensamma fretaget IMI har redan internkontrollfrfaranden som ska ge rimlig skerhet om att bedrgerier och oriktigheter frebyggs och upptcks (frhandskontroller av betalningar, en policy fr intressekonflikter och efterhandsrevisioner hos bidragsmottagare).
The Joint Undertaking is implementing the measures in the action plan, such as making use of Commission databases to identify excluded organisations or potential double funding (21), in accordance with the agreed timetable. 
Det gemensamma fretaget genomfr tgrderna i tgrdsplanen, till exempel anvnder det kommissionens databaser fr att identifiera uteslutna organisationer eller potentiell dubbelfinansiering (16), i enlighet med den verenskomna tidtabellen.
The IAS completed an audit on the evaluation and selection process for Horizon 2020 grant proposals at the FCH 2 Joint Undertaking in November 2015. 
I februari 2015 avslutade tjnsten fr internrevision en revision av frhandskontrollerna inom bidragsfrvaltningen vid det gemensamma fretaget IMI 2.
41. The ex post audits performed during 2015 covered projects funded by the Joint Undertaking under FP7. 
107Đ110. De efterhandsrevisioner som gjordes under 2015 gllde projekt som det gemensamma fretaget finansierade inom sjunde ramprogrammet.
The audit approach for Horizon 2020 projects is set out in the Research common ex post audit strategy for Horizon 2020. 
Den revisionsmetod som ska anvndas fr Horisont 2020-projekt anges i den gemensamma strategin fr efterhandsrevision av Horisont 2020.
The ex post audits for projects funded by the Joint Undertaking under Horizon 2020 will start in 2016. 
Efterhandsrevisionerna av projekt som finansieras av det gemensamma fretaget inom Horisont 2020 kommer att inledas under 2016.
(20) For example, the setting-up of a Common Support Centre, with a centralised audit service and harmonised business processes for EU research bodies. 
(15) Till exempel inrttandet av en gemensam stdtjnst med en centraliserad revisionsavdelning och harmoniserade affrsprocesser fr EU:s forskningsorgan.
EN C 473/52 Official Journal of the European Union 16.12.2016 FOLLOW-UP OF PREVIOUS OBSERVATIONS Monitoring and reporting of project research results 29. 
118Đ132. SV C 473/62 Europeiska unionens officiella tidning 16.12.2016 Intressekonflikter 28.
EN 16.12.2016 Official Journal of the European Union C 473/53 ANNEX Fuel Cells and Hydrogen 2 Joint Undertaking (Brussels) Competences and activities Areas of Union competence deriving from the Treaty (Articles 187 and 188 of the Treaty on the Functioning of the European Union) Competences of the Joint Undertaking as defined in Council Regulation (EU) No 559/2014 Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 providing for public-private partnerships in the form of Joint Technology Initiatives which could be implemented through Joint Undertakings within the meaning of Article 187 of the TFEU and Regulation (EU) No 1291/2013 of the European Parliament and of the Council (ÔHorizon 2020Ő) which aims to have a greater impact on research and innovation by combining Horizon 2020 and private-sector funds within public-private partnerships in key areas where research and innovation can contribute to the UnionŐs wider competitiveness goals, leverage private investment, and help tackle societal challenges. Council Regulation (EU) No 559/2014 of 6 May 2014 establishing the FCH 2 Joint Undertaking. Objectives The Fuel Cells and Hydrogen 2 Joint Undertaking shall have the following objectives: (a) to contribute to the implementation of Regulation (EU) No 1291/2013, and in particular the Secure, Clean and Efficient Energy Challenge and the Smart, Green and Integrated Transport Challenge under Annex I, Part III to Decision 2013/743/ EU; (b) to contribute to the objectives of the Joint Technology Initiative on Fuel Cells and Hydrogen, through the development of a strong, sustainable and globally competitive fuel cells and hydrogen sector in the Union. 
Ml Enligt artikel 2 i rdets frordning (EU) nr 557/2014 ska det gemensamma fretaget IMI 2 ha fljande ml: a) Att i enlighet med artikel 25 i frordning (EU) nr 1291/2013 stdja utvecklingen och genomfrandet av forskning fre det konkurrensutsatta stadiet och av innovationsverksamhet av strategisk betydelse fr unionens konkurrenskraft och industriella ledarskap eller fr hanteringen av srskilda samhllsutmaningar, srskilt som beskrivs i delarna II och III i bilaga I till beslut 2013/743/EU, och i synnerhet utmaningen att frbttra de europeiska medborgarnas hlsa och vlbefinnande. b) Att bidra till uppnendet av mlen fr det gemensamma teknikinitiativet fr innovativa lkemedel, i synnerhet fr att i) ka andelen framgngsrika kliniska prvningar av prioriterade lkemedel som identifierats av Vrldshlsoorganisationen, ii) dr det r mjligt minska tiden fram till kliniska koncepttest inom lkemedelsutveckling, t.ex. fr cancer samt immunologiska, respiratoriska, neurologiska och neurodegenerativa sjukdomar, iii) utveckla nya behandlingsmetoder fr sjukdomar fr vilka det finns ett omfattande icke tillgodosett behov (t.ex.
C 473/54 Official Journal of the European Union 16.12.2016 EN Governance as defined in Council Regulation (EU) No 559/2014 The bodies of the FCH 2 Joint Undertaking are: 1. The Governing Board The Governing Board is the main decision-making body of the FCH 2 Joint Undertaking. 
C 473/64 Europeiska unionens officiella tidning 16.12.2016 SV Organisation Det gemensamma fretaget IMI 2:s styrande organ ska vara i) styrelsen, ii) verkstllande direktren, iii) vetenskapliga kommittn, iv) gruppen med staternas fretrdare och v) forumet fr intressenter.
2. The Executive Director The Executive Director is responsible for the day-to-day management of the Joint Undertaking and is its legal representative. 
Den verkstllande direktren r hgsta chef med ansvar fr den dagliga ledningen av det gemensamma fretaget IMI 2 i enlighet med styrelsens beslut och fr std av ett verkstllande kontor.
The Scientific Committee Composed of up to nine members reflecting a balanced representation of world-class expertise from academia, industry and regulatory bodies. 
Den vetenskapliga kommittn, gruppen med staternas fretrdare och forumet fr intressenter r det gemensamma fretaget IMI 2:s rdgivande organ.
See the FCH 2 JU Annual Activity Report for 2015 at to the http://www.fch.europa.eu/page/annual-activity-reports Source: information supplied by the FCH 2 Joint Undertaking. 
Det gemensamma fretaget IMI 2:s rliga verksamhetsrapport 2015 kommer att vara tillgnglig p www.imi.europa.eu Klla: Uppgifter frn det gemensamma fretaget IMI 2.
12.12.2017 Official Journal of the European Union C 426/49 EN REPORT on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year 2016, together with the Joint UndertakingŐs reply (2017/C 426/07) CONTENTS INTRODUCTION ........................... ............................ .. 
12.12.2017 Europeiska unionens officiella tidning C 426/49 SV RAPPORT om rsredovisningen fr det gemensamma fretaget fr initiativet fr innovativa lkemedel (IMI) fr budgetret 2016 med det gemensamma fretagets svar (2017/C 426/07) INNEHLL INLEDNING.............................................................
Establishment of the IMI Joint Undertaking . . . ............................ .. 
Organisation ........................................................
Governance........................... ............................ .. 
Ml...............................................................
Opinion on the legality and regularity of payments underlying the accounts . . . . . . . . Responsibilities of management and those in charge of governance . . . . . . . . . . . . . . . 
Genomfrandet av den flerriga budgeten inom sjunde ramprogrammet . . . . . . . . . . . GenomfrandetavdenflerrigabudgeteninomHorisont2020 ................. INTERNKONTROLLER .....................................................
ManagementofHorizon2020grants ..................................... Exantechecksandmonitoringofcostclaims ............................... 
Internkontrollramen................................................... FrvaltningavbidragfrnHorisont2020..................................
54 Paragraph Page 1-11 50 1-2 50 3-5 50 6 50 7-11 50 12-24 51 13 51 14 51 15 51 16-18 51 19-23 52 25-31 52 25 52 26-28 52 29-31 53 32-34 53 32 53 33 53 34 53 
54 Punkt Sida 1-11 50 1-2 50 3-5 50 6 50 7-11 50 12-24 51 13 51 14 51 15 51 16-18 51 19-23 52 25-31 52 25 52 26-28 52 29-31 53 32-34 53 32 53 33 53 34 53
EN C 426/50 Official Journal of the European Union 12.12.2017 INTRODUCTION Establishment of the IMI Joint Undertaking 1. 
SV C 426/50 Europeiska unionens officiella tidning 12.12.2017 INLEDNING Bildandet av det gemensamma fretaget IMI 1.
The Initiative on Innovative Medicines (IMI) Joint Undertaking, located in Brussels, was set up in December 2007 (1) for a period of 10 years and started working autonomously on 16 November 2009. 
Det gemensamma fretaget fr initiativet fr innovativa lkemedel (nedan kallat det gemensamma fretaget IMI) ligger i Bryssel, inrttades i december 2007 (1) fr en period p tio r och brjade arbeta sjlvstndigt den 16 november 2009.
In May 2014, the Council adopted a new founding Regulation and extended the lifetime of the Joint Undertaking to 31 December 2024 (2). 
I maj 2014 antog rdet en ny inrttandefrordning och frlngde det gemensamma fretagets livstid till den 31 december 2024 (2).
The IMI Joint Undertaking is a public-private partnership for health research and innovation. 
Det gemensamma fretaget IMI r ett offentligĐprivat partnerskap inom hlsorelaterad forskning och innovation.
The founding members of the Joint Undertaking are the European Union (EU), represented by the Commission, and the pharmaceutical sector, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). 
Grundande medlemmar av det gemensamma fretaget r Europeiska unionen, representerad av kommissionen, och lkemedelssektorn, representerad av den europeiska lkemedelsbranschorganisationen (European Federation of Pharmaceutical Industries and Associations, EFPIA).
The governance structure of the IMI Joint Undertaking includes the Governing Board, the Executive Director, the Scientific Committee, the States Representatives Group, the Strategic Governing Groups and the Stakeholder Forum. 
I det gemensamma fretaget IMI:s organisationsstruktur ingr styrelsen, verkstllande direktren, vetenskapliga kommittn, gruppen med staternas fretrdare, de strategiska styrgrupperna och forumet fr berrda parter.
The Executive Director is responsible for the day-to-day management of the Joint Undertaking. 
Den verkstllande direktren ansvarar fr den dagliga ledningen av det gemensamma fretaget.
The Scientific Committee, the States Representatives Group, the Strategic Governing Groups and the Stakeholder Forum are advisory bodies. 
Vetenskapliga kommittn, gruppen med staternas fretrdare, de strategiska styrgrupperna och forumet fr berrda parter r rdgivande organ.
The Scientific Committee is made up of scientific experts from diverse fields and provides recommendations to the Governing Board. 
Vetenskapliga kommittn bestr av vetenskapliga experter p olika omrden som ger rekommendationer till styrelsen.
The States Representatives Group, consisting of representatives of the EU Member States and the countries associated with the EUŐs research programmes, provides strategic opinions to the Governing Board. 
Gruppen med staternas fretrdare, som bestr av fretrdare fr varje medlemsstat och fr varje land som r associerat till EU:s forskningsprogram, avger strategiska yttranden till styrelsen.
The Strategic Governing Groups, which comprise representatives of pharmaceutical companies, the European Commission and the Scientific Committee, coordinate IMI projects among themselves and with the EUŐs wider research programmes. 
De strategiska styrgrupperna, som bestr av fretrdare fr lkemedelsfretag, Europeiska kommissionen och vetenskapliga kommittn, samordnar IMI-projekt mellan sig och med EU:s bredare forskningsprogram.
The Stakeholder Forum is an annual event, where IMI stakeholders discuss the IMIŐs latest activities and plans. 
Forumet fr berrda parter r ett rligt arrangemang, dr IMI-intressenter diskuterar IMI:s senaste verksamhet och planer.
The objective of the IMI is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. 
Mlet fr det gemensamma fretaget IMI r att frbttra hlsan genom att pskynda utvecklingen av och patienternas tillgng till innovativa lkemedel, srskilt p omrden dr det finns ett medicinskt eller socialt behov som inte tillgodosetts.
The IMI seeks to facilitate collaboration between the key players in healthcare research, including universities, the pharmaceutical and other industries, small-and medium-sized enterprises (SMEs), patient organisations and medicine regulators. 
Det gemensamma fretaget IMI ska frmja samverkan mellan nyckelaktrer inom forskning p hlso-och sjukvrdsomrdet, inbegripet universitet, lkemedelsindustrin och andra branscher, sm och medelstora fretag, patientorganisationer och tillsynsmyndigheter fr lkemedel.
The maximum EU contribution to the activities of the IMI1 programme (2008-2013) is one billion euro, funded from the Seventh Research Framework Programme (FP7) (3). 
EU:s maximala bidrag till det gemensamma fretaget IMI 1:s verksamhet (2008Đ2013) var 1 miljard euro finansierat frn sjunde ramprogrammet fr forskning (3).
Contributions from pharmaceutical sector members must be equal to the EU contribution. 
Bidragen frn medlemmarna frn lkemedelssektorn ska vara lika stora som bidraget frn EU.
The maximum EU contribution to the activities of the IMI2 programme (2014-2024) is 1 638 million euro, to be paid from the Horizon 2020 programme. 
Det maximala bidraget frn EU till IMI 2-programmets verksamhet (2014Đ2024) r 1 638 miljoner euro, vilket ska betalas frn Horisont 2020-programmet.
Of this amount, a maximum of 1 425 million euro can be used to match the contribution of EFPIA, and up to 213 million euro can be used to match contributions from other companies and universities that decide to join the IMI Joint Undertaking as members or associated partners (4). 
Av detta belopp kan maximalt 1 425 miljoner euro anvndas till att matcha bidraget frn den europeiska lkemedelsbranschorganisationen, och upp till 213 miljoner euro kan anvndas till att matcha bidrag frn andra fretag och universitet som beslutar sig fr att g med i det gemensamma fretaget IMI som medlemmar eller bli associerade partner (4).
(1) Council Regulation (EC) No 73/2008 of 20 December 2007 setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (OJ L 30, 4.2.2008, p. 
(1) Rdets frordning (EG) nr 73/2008 av den 20 december 2007 om bildande av det gemensamma fretaget fr genomfrande av det gemensamma teknikinitiativet fr innovativa lkemedel (EUT L 30, 4.2.2008, s.
(2) Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking (OJ L 169, 7.6.2014, p. 
(2) Rdets frordning (EU) nr 557/2014 av den 6 maj 2014 om bildande av det gemensamma fretaget fr initiativet fr innovativa lkemedel 2 (EUT L 169, 7.6.2014, s.
(3) Article 5(1) of Regulation (EC) No 73/2008. 
(3) Artikel 5.1 i frordning (EG) nr 73/2008.
(4) Article 3(1) of Regulation (EU) No 557/2014. 
(4) Artikel 3.1 i frordning (EU) nr 557/2014.
12.12.2017 Official Journal of the European Union C 426/51 9. 
SV 12.12.2017 Europeiska unionens officiella tidning C 426/51 9.
EFPIA is to contribute resources of at least 1 425 million euro. 
Den europeiska lkemedelsbranschorganisationen ska bidra med resurser motsvarande minst 1 425 miljoner euro.
Other members or associated partners of the IMI2 programme are to contribute resources corresponding to the amounts they committed when becoming a member or an associated partner. 
Andra medlemmar av eller associerade partner i IMI 2-programmet ska bidra med resurser motsvarande de belopp som de tog sig nr de blev medlemmar eller associerade partner.
The administrative costs of the Joint Undertaking are limited to 85,2 million euro, to be covered by the cash contributions of the members, divided equally on an annual basis between the EU and the industry members (5). 
De administrativa kostnaderna fr det gemensamma fretaget begrnsas till 85,2 miljoner euro och ska tckas genom kontantbidrag frn medlemmarna som frdelas lika p rlig basis mellan EU och industrimedlemmarna (5).
In 2016, the payment budget for the IMI Joint Undertaking was 263,4 million euro (2015: 195 million euro). 
Det gemensamma fretaget IMI:s budget fr betalningar 2016 var 263,4 miljoner euro (2015: 195 miljoner euro).
At 31 December 2016, the Joint Undertaking employed 41 staff (2015: 35) (6). 
Den 31 december 2016 hade det gemensamma fretaget 41 anstllda (2015: 35) (6).
OPINION 12. 
UTTALANDE 12.